Shares of Harrow Inc. (HROW) are up over 20% at $28.42 in premarket trading Tuesday, following encouraging preliminary financial results for the fourth quarter and year ended December 31, 2024, as well as revenue guidance for 2025.
This eye care pharmaceutical company is engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the U.S. market. The company sells prescription medications directly through its pharmacy, outsourcing facility, and third-party logistics (3PL) partner.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.